Intec Pharma (NTEC) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of Intec Pharma (NASDAQ:NTEC) from a hold rating to a buy rating in a report released on Saturday morning.

Several other research firms have also weighed in on NTEC. Zacks Investment Research lowered shares of Intec Pharma from a buy rating to a hold rating in a report on Thursday, November 8th. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the stock a buy rating in a report on Thursday, November 15th. HC Wainwright set a $16.00 price objective on shares of Intec Pharma and gave the stock a buy rating in a report on Wednesday, October 24th. Finally, Roth Capital assumed coverage on shares of Intec Pharma in a report on Friday, October 5th. They set a buy rating and a $8.50 price objective for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $11.60.

NASDAQ NTEC opened at $7.65 on Friday. The company has a market cap of $227.15 million, a PE ratio of -4.64 and a beta of 0.74. Intec Pharma has a 1-year low of $3.55 and a 1-year high of $7.98.

Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. Equities research analysts forecast that Intec Pharma will post -1.33 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Acuta Capital Partners LLC grew its stake in shares of Intec Pharma by 8.7% during the second quarter. Acuta Capital Partners LLC now owns 2,962,568 shares of the biotechnology company’s stock valued at $13,035,000 after purchasing an additional 238,285 shares during the last quarter. Prosight Management LP grew its stake in shares of Intec Pharma by 18.8% during the third quarter. Prosight Management LP now owns 1,337,191 shares of the biotechnology company’s stock valued at $7,555,000 after purchasing an additional 212,038 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Intec Pharma by 2,096.1% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 658,835 shares of the biotechnology company’s stock valued at $3,722,000 after purchasing an additional 628,835 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Intec Pharma by 13.0% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 589,996 shares of the biotechnology company’s stock valued at $3,333,000 after purchasing an additional 67,929 shares during the last quarter. Finally, DAFNA Capital Management LLC bought a new stake in shares of Intec Pharma during the second quarter valued at approximately $2,502,000. 39.67% of the stock is currently owned by institutional investors and hedge funds.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Featured Article: Investing in Dividend Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit